back to US directory
us clinical guidance

Possible ovarian cancer and adnexal mass

US ovarian-screening limits and ACR adnexal-mass imaging; oncology referral and procedural planning remain explicit evidence gaps.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with ovaries who have persistent abdominal or pelvic symptoms, a palpable or incidental adnexal mass, ascites or inherited ovarian-cancer risk. Acute pelvic pain, pregnancy-related conditions and known hereditary syndromes need their matching emergency or genetics pathways.
sources for this section:USPSTF 2018ACR Adnexal Mass

The Bottom Line

  • Do not screen asymptomatic average-risk people with CA-125, transvaginal ultrasound or pelvic examination; the USPSTF Grade D recommendation found no mortality benefit and meaningful false-positive surgical harm.
  • The screening recommendation does not apply to symptoms or a known mass. Persistent bloating or increased abdominal size, pelvic or abdominal pain, early satiety, urinary change or unexplained systemic decline requires clinical evaluation.
  • Use pelvic ultrasound鈥攖ransabdominal and transvaginal with Doppler as appropriate鈥攁s the usual initial imaging for a clinically suspected nonacute adnexal mass, recording morphology rather than calling every mass a cyst.
  • Interpret CA-125 only in context: it can be normal in ovarian cancer and elevated by benign conditions and must not diagnose, exclude or screen for cancer by itself.
  • Do not infer gynecologic-oncology referral criteria or preoperative timing from these sources: the USPSTF source addresses screening and the ACR source addresses imaging appropriateness.
sources for this section:USPSTF 2018ACR Adnexal Mass

Practical clinical workflow

1
Record symptom duration and frequency, menopausal status, pregnancy possibility, bleeding, bowel and urinary change, weight, prior surgery and endometriosis, and personal or family breast, ovarian, pancreatic or prostate cancer.
2
Examine abdomen and pelvis as appropriate for mass, tenderness, ascites and nodes, while recognizing that a normal examination does not exclude an adnexal lesion.
3
Obtain pelvic ultrasound with Doppler and pregnancy testing when relevant; use MRI for indeterminate characterization and CT when staging or another abdominal process is the clinical question.
4
Integrate morphology, menopausal status, symptoms, tumor markers when indicated and inherited risk; avoid serially observing a suspicious lesion without a named decision point.
5
Complete the source-supported imaging question and use a separate exact current gynecologic or oncology authority for surveillance, referral, biopsy and operative planning.
sources for this section:USPSTF 2018ACR Adnexal Mass

Safety boundaries and escalation

  • Sudden severe unilateral pelvic pain, vomiting, peritoneal signs or hemodynamic compromise requires emergency assessment for torsion, rupture, hemorrhage or ectopic pregnancy.
  • New ascites, bowel obstruction, pleural symptoms or rapid functional decline warrants expedited cancer and acute-care assessment.
  • Biopsy, cyst drainage and operative-staging recommendations are outside the attached screening and imaging sources and must not be presented here without an exact current oncology authority.
  • A strong inherited-cancer history warrants genetics evaluation even when today鈥檚 imaging is normal and should not be managed as average-risk screening.
sources for this section:USPSTF 2018ACR Adnexal Mass

Localization

The US sources separate a Grade D population-screening recommendation from imaging of a clinically suspected mass. They do not establish gynecologic-oncology referral or procedural rules.
sources for this section:USPSTF 2018ACR Adnexal Mass

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Preventive Services Task ForceOvarian Cancer: ScreeningFinal Recommendation Statement; Grade D 路 published 2018-02-13 路 accessed 2026-08-20
    view source
  2. American College of RadiologyACR Appropriateness Criteria: Clinically Suspected Adnexal Mass, No Acute SymptomsDOI 10.1016/j.jacr.2024.02.017 路 2023 update 路 published 2024-06-01 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.